Frovatriptan and Menstrual Migraine (FROVA)
Mapping CNS Changes to Frovatriptan Administration in Acute Treatment of Prodrome or Preventative Treatment of Menstrual Migraine (MM)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Belmont, Massachusetts, United States, 02478
- Neuroimaging Center, McLean Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female
- Regular Menstrual Phase
- Menstrual Migraine
- No significant medical history (Significant medical history of such as seizure disorder, diabetes, alcoholism, cardiac disease including coronary artery disease, psychiatric problems; drug addiction, respiratory problems, liver disease, etc.)
- No significant medication history, except for migraine
- All patients will be currently taking or have previously taken triptan medications for migraine
- Weight, <285 pounds
- Not claustrophobic
- No contraindication to taking triptans
Exclusion Criteria:
- Age <18
- Significant medical problems (aside from pain before, during and after migraine episodes)
- Positive drug of abuse screen (excluding medications currently prescribed for their clinical condition, e.g. opioids, benzodiazepines, etc.)
- Positive alcohol screen
- Women taking oral contraceptives
- Claustrophobia
- History of dermatological hypersensitivity in the facial area
- Positive history of cardiac problems/ abnormalities seen in EKG at initial screening visit
- Pregnancy
- Sensory loss detected on Quantitative Sensory Testing at screening
- Significant alcohol history (ingestion of 5 or more glasses (> 40 oz) of alcohol per week)
- Metal implants of any type (including dental bridges, crowns, retainers, orthodontic devices e.g. braces, etc.)
- Tattoos containing metallic ink on the neck, shoulders, upper arm and head (which could become heated up in the scanner, and potentially cause blistering or burning)
- Cardiac pacemakers
- Aneurysm clips and other vascular stents, filters, clips or other devices
- Prosthetic heart valves
- Other prostheses
- Neuro-stimulator devices
- Implanted infusion pumps
- Cochlear (ear) implants
- Ocular (eye) implants or known metal fragments in eyes
- Exposure to shrapnel or metal filings (sheet metal workers, welders, and others)
- Other metallic surgical hardware in vital areas
- Use of any of the following medications:
- Propanolol/ Inderol
- SSRI's: citalopram/ Celexa, Lepraxo, paroxetine/ Paxil, fluoxetine/ Prozac, Sarafem, Symbyax, sertraline/ Zoloft, Fluvoxamine/ Luvox
- SNRI's: duloxetine/ Cymbalta, venlafaxine/ Effexor
- triptans: sumatriptan/ Imitrex, naratriptan/ Amerge, zolmitriptan/ Zomig, rizatriptan/ Maxalt, eletriptan/ Relpax, almotriptan/ Axert
- ergotamine type medicines: Bellergal, Cafergot, Ergomar, Wiraine, Migranal/ DHE45, Sansert
- ketoconazole (Nizoral, Fungoral)
- itraconazole (Sporanox)
- ritonavir (Norvir)
- erythromycin (Erythrocin)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Frovatriptan
All subjects will be taking Frovatriptan tablets within 48 hours prior to the scan session (Visit 2).
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2009-P-001452
- 400479 (OTHER_GRANT: Endo Pharmaceuticals, Inc.)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.